Her‐2/neu Gene Amplification in Low to Moderately Expressing Breast Cancers: Possible Role of Chromosome 17/Her‐2/neu Polysomy

No abstract is available for this paper.

• Publication year

  2001

• Venue

  The Breast Journal

• Publication date

  2001-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1524-4741.2001.21018.xPMID 11906444
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of PathVysion and INFORM Fluorescence In Situ Hybridization Kits for Assessment of HER-2/neu Status in Breast Carcinoma

  2012cited by this paper
• The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

  2000cited by this paper
• Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

  2000cited by this paper
• Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization

  2000cited by this paper
• Comparison of PathVysion and INFORM fluorescence in situ hybridization kits for assessment of HER-2/neu status in breast carcinoma.

  2000cited by this paper
• Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

  2000cited by this paper
• Widespread aneuploidy revealed by DNA microarray expression profiling

  2000cited by this paper
• HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma.

  2000cited by this paper
• c‐erbB‐2 over‐expression in amplified and non‐amplified breast carcinoma samples

  1999cited by this paper
• Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.

  1999cited by this paper
• Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.

  1999cited by this paper
• The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

  1998cited by this paper
• erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

  1998cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

  1996cited by this paper
• c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

  1996cited by this paper
• c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer.

  1995cited by this paper
• Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

  1994cited by this paper
• Prognostic value of immunohistochemical staining for proliferating cell nuclear antigen, p53, and c-erbB-2 in sebaceous gland carcinoma and sweat gland carcinoma: comparison with histopathological parameter.

  1994cited by this paper
• c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

  1994cited by this paper
• Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation

  1994cited by this paper
• Clinical trials referral resource. NCI-sponsored trials of interleukin-6 (IL-6).

  1993cited by this paper
• Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers.

  1992cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Correlation of In Situ HER2 RNA Expression With HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Categories in Breast Cancer.

  2023cites this paper
• Equivocal (HER2 IHC 2+) breast carcinomas: gene–protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits

  2018cites this paper
• Investigating The Impact of Polysomy 17 in Breast Cancer Patients Without Amplification Through Meta-Analysis

  2018cites this paper
• The Detection of HER2 Gene Amplification in Breast Cancerby upQMPSF

  2017cites this paper
• Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer:  A Cohort Study Emphasizing Equivocal Cases.

  2016cites this paper
• HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients

  2016cites this paper
• Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification.

  2015cites this paper
• Optimization of Real Time PCR for Precise Measurement of HER2 Overexpression in Breast Cancer Specimens

  2015cites this paper
• The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831

  2015cites this paper
• Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP 17 and HER 2 signals

  2014cites this paper
• High‐level ERBB2 gene amplification is associated with a particularly short time‐to‐metastasis, but results in a high rate of complete response once trastuzumab‐based therapy is offered in the metastatic setting

  2014cites this paper
• Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.

  2014cites this paper
• HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

  2014cites this paper
• Evaluation of chromosome 17 polysomy in breast cancer by FISH analysis of whole nuclei, and its clinicopathological significance

  2014cites this paper
• Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.

  2014cites this paper
• Theranostic and molecular classification of breast cancer.

  2014cites this paper
• Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification

  2013cites this paper
• Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

  2013cites this paper
• Assessment of HER-2 gene overexpression in Isfahan province breast cancer patients using Real Time RT-PCR and immunohistochemistry.

  2013cites this paper
• Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status

  2012cites this paper
• Predictive and Prognostic Marker Testing in Breast Pathology: Immunophenotypic Subclasses of Disease

  2012cites this paper
• Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?

  2012cites this paper
• HER-2/neu gene amplification assessment in breast cancer patients in Isfahan province by real time PCR, differential PCR and immunohistochemistry.

  2012cites this paper
• HER2 Expression in Breast Cancer With Nonamplified HER2 and Gains of Chromosome 17 Centromere

  2012cites this paper
• Significance of biomarker discordance in breast cancer from the pathologist's perspective

  2012cites this paper
• Chapter 19 – Immunohistology of the Breast

  2011cites this paper
• Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.

  2011cites this paper
• HER-2 Protein Overexpressing Breast Cancer Without Gene Amplification Shows Higher Hormone Receptor Expression Than HER-2 Protein Overexpressing Breast Cancer With Gene Amplification

  2011cites this paper
• Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization and immunohistochemistry in saudi female breast cancer.

  2010cites this paper
• Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization for the Analysis of HER 2 / neu and Topoisomerase II-alpha Status in Human Breast Cancer

  2010cites this paper
• HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

  2010cites this paper
• Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization for the Analysis of HER2/neu and Topoisomerase II-alpha Status in Human Breast Cancer İnsan Meme Kanserinde Topoizomeraz II-alfa ve HER2/neu Saptanmasinda İmmünohistokimya ve Floresan İn Situ Hibridizasyon Yöntemlerinin Karşil

  2010cites this paper
• Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.

  2010cites this paper
• Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing.

  2009cites this paper
• Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.

  2009cites this paper
• Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

  2009cites this paper
• Effect of High Copy Number of HER2 Associated With Polysomy 17 on HER2 Protein Expression in Invasive Breast Carcinoma

  2009cites this paper
• Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

  2009cites this paper
• Her-2 Immunohistochemical Expression in Oral Squamous Cell Carcinomas is Associated with Polysomy of Chromosome 17, Not Her-2 Amplification

  2009cites this paper
• HER-2/neu status in breast cancer The effect of chromosome 17 polysomy on

  2009cites this paper
• Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria.

  2009cites this paper
• Evaluation of HER2 in breast cancer: reality and expectations.

  2009cites this paper
• Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.

  2008cites this paper
• HER-2, TOP2A and chromosome 17 alterations in breast cancer

  2008cites this paper
• Lower HER‐2/chromosome enumeration probe 17 ratio in cytologic HER‐2 fluorescence in situ hybridization for breast cancers

  2008cites this paper
• HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.

  2008cites this paper
• Polysomy 17 and HER-2 amplification: true, true, and unrelated.

  2008cites this paper
• No Strong Association Between HER-2/neu Protein Overexpression and Gene Amplification in High-grade Invasive Urothelial Carcinomas

  2008cites this paper
• A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility

  2007cites this paper
• Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR.

  2007cites this paper
• HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.

  2007cites this paper
• The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer

  2007cites this paper
• Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy

  2007cites this paper
• Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer.

  2006cites this paper
• Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer

  2006cites this paper
• Heterogeneity of Invasive Ductal Carcinoma: Proposal for a Hypothetical Classification

  2006cites this paper
• Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus.

  2006cites this paper
• How accurate is the antiprimer quenching-based real-time PCR for detection of Her2/neu in clinical cancer samples?

  2006cites this paper
• HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists.

  2006cites this paper
• Chapter 17 – Immunohistology of the Breast

  2006cites this paper
• Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

  2005cites this paper
• Re: Lottner et al. simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin‐embedded breast cancer. J Pathol 2005; 205: 577–584

  2005cites this paper
• Numerical Aberrations of Chromosomes 1 and 7 by Fluorescent in Situ Hybridization and DNA Ploidy Analysis in Breast Cancer

  2005cites this paper
• Real‐time reverse transcription‐PCR and fluorescence in‐situ hybridization are complementary to understand the mechanisms involved in HER‐2/neu overexpression in human breast carcinomas

  2005cites this paper
• The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast: A Fluorescent In Situ Hybridization, Immunohistochemical, and Isotopic mRNA In Situ Hybridization Study

  2005influential citation
• Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

  2005cites this paper
• HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ Hybridization

  2005cites this paper
• Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry

  2005cites this paper
• HER-2/neu evaluation in breast cancer are we there yet?

  2004cites this paper
• Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma.

  2004cites this paper
• Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.

  2004cites this paper
• HER-2/neu Assessment in Primary Chemotherapy Treated Breast Carcinoma: No Evidence of Gene Profile Changing

  2003cites this paper
• Her-2/neu Gene Amplification in Familial vs Sporadic Breast Cancer

  2003cites this paper
• Her-2/neu gene amplification in familial vs sporadic breast cancer. Impact on the behavior of the disease.

  2003cites this paper
• Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer.

  2003cites this paper
• HER2 testing and correlation with efficacy of trastuzumab therapy.

  2002cites this paper